Batch COA Registry & Analytical Standards
Verify active production lot numbers, analytical testing methods (RP-HPLC, SEC-HPLC, SDS-PAGE, ESI-MS, and USP <71>/<85> sterility), and request lot-specific raw analytical chromatograms for institutional documentation.
RP-HPLC & ESI-MS Release
Linear and cyclic synthetic peptides are qualified via reverse-phase C18 chromatography (UV 214/220 nm, ≥99.0% main peak) and ESI-MS monoisotopic mass confirmation (±0.1 Da). Co-lyophilized multi-peptide blends use gradient RP-HPLC to resolve every constituent peak individually.
SEC-HPLC & SDS-PAGE Integrity
Folded recombinant proteins and glycoprotein heterodimers (rhGH 191-aa, IGF-1 LR3, Follistatin, ACE-031, hCG, hMG) are evaluated via Size-Exclusion Chromatography (SEC-HPLC) and reducing/non-reducing SDS-PAGE to confirm monomeric integrity and detect aggregates.
Lot-Specific Chromatogram Access
Institutional laboratories requiring batch-specific raw analytical reports, independent third-party testing documentation, or salt-content breakdowns prior to procurement can request documentation directly by lot code.
Active Batch Analytical Registry (66 Lots)
Search by compound name, CAS registry number, analytical method, or lot code (e.g., SL-2026-110)
| Compound | Batch Lot # | CAS Number | Release Spec | Analytical Method | Release Date |
|---|---|---|---|---|---|
| 5-Amino-1MQ (10 mg) | SL-2026-101 | 42464-96-0 | ≥99.0% (Chromatographic Peak) | HPLC-UV + LC-MS (Small-Molecule Verification) | 2026-10-28 |
| ACE-031 (1 mg) | SL-2026-102 | 1169766-01-1 | ≥99.0% (Monomeric Purity) | SEC-HPLC + SDS-PAGE (Reducing & Non-Reducing) | 2026-10-28 |
| Acetic Acid Water (10 ml) | SL-2026-103 | 64-19-7 (0.6% v/v in USP Water) | Pass (USP <71>/<85>) | USP Sterility & LAL Endotoxin (<0.25 EU/mL) | 2026-10-28 |
| Adipotide (5 mg) | SL-2026-104 | 859216-15-2 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| AICAR (50 mg) | SL-2026-105 | 2627-69-2 | ≥99.0% (Chromatographic Peak) | HPLC-UV + LC-MS (Small-Molecule Verification) | 2026-10-28 |
| AOD-9604 (5 mg) | SL-2026-106 | 221231-10-3 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| ARA 290 (16 mg) | SL-2026-107 | 1208243-50-8 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| B12 (10 ml) | SL-2026-108 | 13422-55-4 | Pass (USP <71>/<85>) | USP Sterility & LAL Endotoxin (<0.25 EU/mL) | 2026-10-28 |
| Bacteriostatic Water (10 ml) | SL-2026-109 | 7732-18-5 (Water) / 100-51-6 (0.9% Benzyl Alcohol) | Pass (USP <71>/<85>) | USP Sterility & LAL Endotoxin (<0.25 EU/mL) | 2026-10-28 |
| BPC-157 (5 mg) | SL-2026-110 | 137525-51-0 | ≥99.2% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| BPC-157 10mg + TB-500 10mg (10mg + 10mg) | SL-2026-111 | 137525-51-0 / 77591-33-4 | ≥99.0% (Resolved Constituent Peaks) | Gradient RP-HPLC (Multi-Peak Resolution) + ESI-MS | 2026-10-28 |
| BPC-157 5mg + TB-500 5mg (5mg + 5mg) | SL-2026-112 | 137525-51-0 / 77591-33-4 | ≥99.0% (Resolved Constituent Peaks) | Gradient RP-HPLC (Multi-Peak Resolution) + ESI-MS | 2026-10-28 |
| Cagrilintide + Semaglutide (2.5mg + 2.5mg) | SL-2026-113 | 1415456-99-3 / 910463-68-2 | ≥99.0% (Resolved Constituent Peaks) | Gradient RP-HPLC (Multi-Peak Resolution) + ESI-MS | 2026-10-28 |
| Cagrilintide (5 mg) | SL-2026-114 | 1415456-99-3 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Cerebrolysin (60 mg) | SL-2026-115 | 12656-61-0 | Pass (Standardized Low-MW Profile) | SEC-HPLC Peptide Fingerprint + Amino Acid Analysis | 2026-10-28 |
| CJC-1295 (no DAC) (5 mg) | SL-2026-116 | 863288-34-0 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| CJC-1295 (5 mg) | SL-2026-117 | 863288-34-0 (with DAC) | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| CJC-1295 + Ipamorelin (5mg + 5mg) | SL-2026-118 | 863288-34-0 / 170851-70-4 | ≥99.0% (Resolved Constituent Peaks) | Gradient RP-HPLC (Multi-Peak Resolution) + ESI-MS | 2026-10-28 |
| Custom Peptide Batch (Custom (10mg–5g)) | SL-2026-119 | Sequence-Specific (Custom SPPS) | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| DSIP (5 mg) | SL-2026-120 | 62568-57-4 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Epitalon (10 mg) | SL-2026-121 | 307297-39-8 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Follistatin (1 mg) | SL-2026-122 | 117628-82-7 | ≥99.0% (Monomeric Purity) | SEC-HPLC + SDS-PAGE (Reducing & Non-Reducing) | 2026-10-28 |
| FOXO4-DRI (10 mg) | SL-2026-123 | 2460055-10-9 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| GHK-Cu (50 mg) | SL-2026-124 | 49557-75-7 | ≥99.2% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| GHRP-2 (5 mg) | SL-2026-125 | 158861-67-7 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| GHRP-6 (5 mg) | SL-2026-126 | 87616-84-0 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Glow Blend (70 mg (50/10/10)) | SL-2026-127 | 49557-75-7 / 137525-51-0 / 77591-33-4 | ≥99.0% (Resolved Constituent Peaks) | Gradient RP-HPLC (Multi-Peak Resolution) + ESI-MS | 2026-10-28 |
| Glutathione (1500 mg) | SL-2026-128 | 70-18-8 | ≥99.0% (Chromatographic Peak) | HPLC-UV + LC-MS (Small-Molecule Verification) | 2026-10-28 |
| Gonadorelin (10 mg) | SL-2026-129 | 33515-09-2 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| HCG (5000 IU) | SL-2026-130 | 9002-61-3 | ≥99.0% (Monomeric Purity) | SEC-HPLC + SDS-PAGE (Reducing & Non-Reducing) | 2026-10-28 |
| Hexarelin (5 mg) | SL-2026-131 | 140703-51-1 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| HGH (10 IU (3.33 mg)) | SL-2026-132 | 12629-01-5 | ≥99.0% (Monomeric Purity) | SEC-HPLC + SDS-PAGE (Reducing & Non-Reducing) | 2026-10-28 |
| HMG (75 IU) | SL-2026-133 | 61489-71-2 | ≥99.0% (Monomeric Purity) | SEC-HPLC + SDS-PAGE (Reducing & Non-Reducing) | 2026-10-28 |
| IGF-1 LR3 (1 mg) | SL-2026-134 | 946870-92-4 | ≥99.0% (Monomeric Purity) | SEC-HPLC + SDS-PAGE (Reducing & Non-Reducing) | 2026-10-28 |
| Ipamorelin (5 mg) | SL-2026-135 | 170851-70-4 | ≥99.2% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Kisspeptin (5 mg) | SL-2026-136 | 374675-21-5 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Klow (80 mg (50/10/10/10)) | SL-2026-137 | 49557-75-7 / 137525-51-0 / 77591-33-4 / 67727-97-3 | ≥99.0% (Resolved Constituent Peaks) | Gradient RP-HPLC (Multi-Peak Resolution) + ESI-MS | 2026-10-28 |
| KPV (10 mg) | SL-2026-138 | 67727-97-3 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| L-carnitine (500 mg/ml (10 ml)) | SL-2026-139 | 541-15-1 | Pass (USP <71>/<85>) | USP Sterility & LAL Endotoxin (<0.25 EU/mL) | 2026-10-28 |
| Lemon Bottle (10 ml) | SL-2026-140 | 83-88-5 / 8002-43-5 / 9001-00-7 | Pass (USP <71>/<85>) | USP Sterility & LAL Endotoxin (<0.25 EU/mL) | 2026-10-28 |
| Lipo-C (10 ml) | SL-2026-141 | 63-68-3 / 87-89-8 / 67-48-1 | Pass (USP <71>/<85>) | USP Sterility & LAL Endotoxin (<0.25 EU/mL) | 2026-10-28 |
| LL-37 (5 mg) | SL-2026-142 | 154947-66-7 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Mazdutide (5 mg) | SL-2026-143 | 2259884-03-0 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Melanotan I (10 mg) | SL-2026-144 | 75921-69-6 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Melanotan II (10 mg) | SL-2026-145 | 121062-08-6 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Melatonin (10 mg) | SL-2026-146 | 73-31-4 | ≥99.0% (Chromatographic Peak) | HPLC-UV + LC-MS (Small-Molecule Verification) | 2026-10-28 |
| MOTS-c (10 mg) | SL-2026-147 | 1627580-64-6 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| NAD+ (500 mg) | SL-2026-148 | 53-84-9 | ≥99.2% (Chromatographic Peak) | HPLC-UV + LC-MS (Small-Molecule Verification) | 2026-10-28 |
| Oxytocin (5 mg) | SL-2026-149 | 50-56-6 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| PEG-MGF (2 mg) | SL-2026-150 | 108174-48-7 (MGF core, PEGylated) | ≥99.0% (PEGylated Fraction) | SEC-HPLC + MALDI-TOF MS (PEG Conjugation) | 2026-10-28 |
| PT-141 (10 mg) | SL-2026-151 | 189691-06-3 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Retatrutide (10 mg) | SL-2026-152 | 2381089-83-2 | ≥99.2% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Selank (5 mg) | SL-2026-153 | 129954-34-3 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Semaglutide (5 mg) | SL-2026-154 | 910463-68-2 | ≥99.2% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Semax (5 mg) | SL-2026-155 | 80714-61-0 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Sermorelin (5 mg) | SL-2026-156 | 86168-78-7 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| SLU-PP-332 (5 mg) | SL-2026-157 | 303760-60-3 | ≥99.0% (Chromatographic Peak) | HPLC-UV + LC-MS (Small-Molecule Verification) | 2026-10-28 |
| SNAP-8 (10 mg) | SL-2026-158 | 868844-74-0 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| SS-31 (10 mg) | SL-2026-159 | 736992-21-2 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Survodutide (5 mg) | SL-2026-160 | 2805997-46-8 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| TB-500 (10 mg) | SL-2026-161 | 77591-33-4 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Tesamorelin (5 mg) | SL-2026-162 | 218949-48-5 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Thymalin (10 mg) | SL-2026-163 | 69558-55-0 (Thymogen / Glu-Trp active core) | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Thymosin Alpha-1 (5 mg) | SL-2026-164 | 62304-98-7 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| Tirzepatide (10 mg) | SL-2026-165 | 2023788-19-2 | ≥99.2% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
| VIP (5 mg) | SL-2026-166 | 40077-57-4 | ≥99.0% (Single Peak) | RP-HPLC (C18, 214nm) + ESI-MS | 2026-10-28 |
4-Stage Analytical Release Protocol
RP-HPLC (C18, UV 214/220 nm) for synthetic peptides and small molecules; SEC-HPLC & SDS-PAGE for recombinant proteins.
ESI-MS or MALDI-TOF mass spectrometry verifies monoisotopic molecular weight and sequence/cyclization integrity.
USP <85> Limulus Amebocyte Lysate assays confirm endotoxin levels <0.5 EU/mg (<0.25 EU/mL for sterile diluents).
Coulometric titration confirms residual lyophilized moisture below 3.0% under dry nitrogen stoppering.